Last reviewed · How we verify
Nicotine lozenge 4 mg
At a glance
| Generic name | Nicotine lozenge 4 mg |
|---|---|
| Sponsor | University of Minnesota |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Rural Smoking Cessation (NA)
- Mindfulness-based Smoking Cessation Enhanced With Mobile Technology (NA)
- Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation (PHASE2)
- STARS (Smoking Treatment And Remote Sampling) Study (PHASE1, PHASE2)
- Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders (PHASE3)
- Project HEALS (Helping and Empowering pAtients for Living a Life Smoke-free (NA)
- Health Systems Reach Interventions Project (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine lozenge 4 mg CI brief — competitive landscape report
- Nicotine lozenge 4 mg updates RSS · CI watch RSS
- University of Minnesota portfolio CI